Premium
Adipocyte‐Derived Anticancer Lipid Droplets
Author(s) -
Liang Tingxizi,
Wen Di,
Chen Guojun,
Chan Amanda,
Chen Zhaowei,
Li Hongjun,
Wang Zejun,
Han Xiao,
Jiang Liping,
Zhu JunJie,
Gu Zhen
Publication year - 2021
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.202100629
Subject(s) - lipid droplet , lipid peroxidation , organelle , endoplasmic reticulum , reactive oxygen species , photodynamic therapy , in vivo , adipocyte , lipid signaling , photosensitizer , biophysics , microbiology and biotechnology , materials science , oxidative stress , biochemistry , chemistry , biology , adipose tissue , enzyme , organic chemistry
Engineering of efficient and safe materials remains a challenge for cancer therapy. Here, the lipid droplet, an organelle in adipocytes, is demonstrated to be a controllable and biocompatible vehicle to deliver anticancer drugs. It is validated that isolated lipid droplets maintain their key physiological functions to interact with other organelles and augment the therapeutic effect of cancer photodynamic therapy by encapsulation with a lipid‐conjugated photosensitizer (Pyrolipid) through a variety of pathways, including generation of reactive oxygen species (ROS); lipid peroxidation; and endoplasmic reticulum (ER) stress. As such, the IC 50 value of Pyrolipid is reduced by 6.0‐fold when loaded into the lipid droplet. Of note, in vivo results demonstrate that engineered lipid droplets induce significant inhibition of tumor growth with minimal side effects.